TABLE 4.
Antimicrobial activity of CAZ-AVI and comparators against variants of blaOXA-48l-like Enterobacterales isolates collected globally in 2016–2020c
| %S | %R | MIC50 | MIC90 | MIC range | |
|---|---|---|---|---|---|
| blaOXA-48 (N = 848) | |||||
| Amikacin | 76.1 | 18.0 | 4 | >64 | 0.25–>64 |
| Aztreonam | 13.1 | 86.0 | 128 | >128 | 0.03–>128 |
| CAZ-AVI | 91.9 | 8.1 | 0.5 | 2 | 0.015–>128 |
| Cefepime | 11.7 | 81.7 | 32 | >32 | 0.12–>32 |
| Colistina | 78.7 | 21.3 | 0.25 | 0.5 | 0.06–>8 |
| Imipenem | 9.0 | 71.1 | 4 | 8 | 0.12–>8 |
| Meropenem | 38.6 | 49.1 | >16 | >16 | 0.06–>16 |
| Pip/Taz | 1.1 | 98.7 | >64 | >128 | 0.25–>128 |
| Tigecyclineb | 95.6 | 0.9 | 0.5 | 2 | 0.06–8 |
| blaOXA-48, MBL (−) (N = 783) | |||||
| Amikacin | 79.2 | 20.8 | 4 | >64 | 0.25–>64 |
| Aztreonam | 13.2 | 86.0 | 128 | >128 | 0.03–>128 |
| CAZ-AVI | 99.5 | 0.5 | 0.5 | 2 | 0.015–>128 |
| Cefepime | 12.6 | 80.3 | >16 | >32 | 0.12–>32 |
| Colistina | 78.9 | 21.0 | 0.5 | >8 | 0.06–>8 |
| Imipenem | 9.7 | 68.8 | 4 | >8 | 0.12–>8 |
| Meropenem | 20.7 | 58.2 | 2 | >16 | 0.015–>16 |
| Pip/Taz | 1.2 | 98.6 | >64 | >128 | 0.25–>128 |
| Tigecyclineb | 95.9 | 0.9 | 0.5 | 2 | 0.06–8 |
| blaOXA-181 (N = 304) | |||||
| Amikacin | 51.6 | 46.4 | 16 | >64 | 0.5–>64 |
| Aztreonam | 6.6 | 91.8 | >64 | >128 | 0.03–>128 |
| CAZ-AVI | 60.2 | 39.8 | 2 | >128 | 0.06–>128 |
| Cefepime | 4.0 | 92.1 | >32 | >32 | 0.12–>32 |
| Colistina | 86.8 | 13.2 | 0.25 | 8 | 0.06–>8 |
| Imipenem | 28.6 | 62.5 | >8 | >8 | 0.12–>8 |
| Meropenem | 30.6 | 67.8 | >16 | >16 | 0.06–>16 |
| Pip/Taz | 0.3 | 99.0 | >64 | >128 | 2–>128 |
| Tigecyclineb | 92.1 | 0.3 | 0.5 | 2 | 0.06–>8 |
| blaOXA-181, MBL (−) (N = 184) | |||||
| Amikacin | 78.8 | 19.0 | 4 | >64 | 0.5–>64 |
| Aztreonam | 7.1 | 91.3 | >64 | >128 | 0.12–>128 |
| CAZ-AVI | 99.5 | 0.5 | 1 | 2 | 0.06–64 |
| Cefepime | 6.0 | 87.5 | >32 | >32 | 0.12–>32 |
| Colistina | 91.3 | 8.7 | 0.25 | 2 | 0.06–>8 |
| Imipenem | 26.1 | 52.7 | 4 | >8 | 0.12–>8 |
| Meropenem | 39.6 | 49.5 | 2 | >16 | 0.06–>16 |
| Pip/Taz | 0.0 | 98.9 | >64 | >128 | 16–>128 |
| Tigecyclineb | 91.9 | 0.5 | 0.5 | 2 | 0.06–>8 |
| blaOXA-232 (N = 496) | |||||
| Amikacin | 23.4 | 73.4 | >64 | >64 | 0.25–>64 |
| Aztreonam | 4.6 | 95.2 | >64 | >128 | 0.12–>128 |
| CAZ-AVI | 65.7 | 34.3 | 1 | >128 | 0.03–>128 |
| Cefepime | 0.4 | 96.6 | >32 | >32 | 2–>32 |
| Colistina | 84.7 | 15.3 | 0.5 | 8 | 0.12–>8 |
| Imipenem | 8.3 | 81.7 | 8 | ≥8 | 0.06–>8 |
| Meropenem | 6.1 | 92.7 | >16 | >16 | 0.25–>16 |
| Pip/Taz | 0.4 | 99.6 | >64 | >128 | 2–>128 |
| Tigecycline | 97.0 | 0.0 | 1 | 2 | 4.0–8 |
| blaOXA-232, MBL (−) (N = 333) | |||||
| Amikacin | 26.4 | 73.0 | >64 | >64 | 1–>64 |
| Aztreonam | 3.9 | 95.8 | >64 | >128 | 0.12–>128 |
| CAZ-AVI | 97.6 | 2.4 | 1 | 2 | 0.015–>128 |
| Cefepime | 0.6 | 95.2 | >32 | >32 | 2–>32 |
| Colistina | 84.4 | 15.6 | 0.5 | 8 | 0.12–>8 |
| Imipenem | 9.3 | 88.3 | 8 | >8 | 0.5–>8 |
| Meropenem | 8.4 | 89.8 | >16 | >16 | 0.25–>16 |
| Pip/Taz | 0.3 | 99.7 | >64 | >64 | 1–>128 |
| Tigecyclineb | 97.0 | 0.0 | 1 | 2 | 0.12–10 |
a
EUCAST breakpoints have been used.
b
FDA-approved breakpoints have been used.
c
N, total number of isolates; S, susceptibility; R, resistance; CAZ-AVI, ceftazidime–avibactam; Pip/taz, piperacillin/tazobactam; ESBL, extended-spectrum β-lactamase; MBL, metallo-β-lactamase.